At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 75 enrolled
Drug / intervention
pregabalindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Multicenter Extension Study To Determine Long Term Safety And Efficacy Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Jan 17, 2008·Updated Jan 26, 2021
In Brief
A Phase 3 clinical trial evaluating pregabalin for Epilepsy. Completed, enrolled 75 participants across 44 sites in 4 countries.
Detailed Summary
This study will evaluate the long term safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy patients for the treatment of partial seizures. This is an extension study to a previous clinical trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesCzechia, Hong Kong, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartApr 2008
Primary CompletionDec 2011
TodayJul 2026
First PostedJan 17, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.5 years ago
Interventions
pregabalindrug
pregabalin